Patents by Inventor John Lowe

John Lowe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tetrahydroquinolines
    Patent number: 7101881
    Abstract: The present invention relates to compounds of formula I wherein X and Y are as defined in the specification, and to pharmaceutical compositions comprising the compound of formula I and a pharmaceutically effective carrier; and to a method useful in treating or preventing in mammals, including humans, a disorder or condition selected from the group consisting of anxiety, depression, dysthymia, major depressive disorder, migraine, post-traumatic stress disorder, avoidant personality disorder, borderline personality disorder and phobias.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: September 5, 2006
    Assignee: Pfizer Inc
    Inventor: John Lowe, III
  • Piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams
    Patent number: 7101885
    Abstract: The present invention relates to compounds of formula I wherein Ar, Y and G are as defined in the specification, a is 1 to 4, Z and W are carbon or nitrogen and n is 1, 2 or 3; and to pharmaceutical compositions comprising the compound of formula I and a pharmaceutically effective carrier; and to a method useful in treating or preventing in mammals, including humans, a disorder or condition selected from the group consisting of anxiety, depression, dysthymia, major depressive disorder, migraine, post-traumatic stress disorder, avoidant personality disorder, borderline personality disorder and phobias.
    Type: Grant
    Filed: June 15, 2004
    Date of Patent: September 5, 2006
    Assignee: Pfizer Inc
    Inventors: John Lowe, III, Mark A. Sanner
  • Attached personal information device
    Publication number: 20060059013
    Abstract: An information storage device may be semi-permanently attached to a wearer. The device can include an outer casing configured to be compatible with long term contact with a human body. A data storage component may store information of the wearer and a transceiver may wirelessly communicate information from the data storage component. The stored information can be, for example, the complete medical history of the wearer, “emergency” medical information, prescriptions, medical warnings (e.g., past history of coronary problems), financial information, social security numbers, or other useful information.
    Type: Application
    Filed: September 13, 2004
    Publication date: March 16, 2006
    Inventor: John Lowe
  • Pharmaceutical compositions comprising a NOS inhibitor
    Publication number: 20060058267
    Abstract: This invention relates to methods of treating neurodegenerative diseases and inhibiting neurological damage, comprising administering to a patient in need of such treatment an N-NOS inhibitor in combination with a GABA-A receptor modulator.
    Type: Application
    Filed: October 25, 2005
    Publication date: March 16, 2006
    Inventors: John Lowe, Robert Volkmann
  • Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
    Publication number: 20050256162
    Abstract: The present invention relates to novel fluoroalkoxybenzylamino derivatives of nitrogen containing heterocyclic compounds, and specifically, to compounds of the formula wherein Q, X1, X2 and X3 are as defined below. These novel compounds are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.
    Type: Application
    Filed: February 24, 2005
    Publication date: November 17, 2005
    Inventors: John Lowe, Terry Rosen
  • Email classifier
    Publication number: 20050144245
    Abstract: An email classifier gives users the ability to efficiently and easily assign category information to email messages. The email classifier may present a graphical window to a user interacting with an email message. Through the graphical window, the user enters information describing at least one category to which the email relates. The email and its associated category information may be archived for later access.
    Type: Application
    Filed: February 24, 2005
    Publication date: June 30, 2005
    Inventor: John Lowe
  • Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
    Publication number: 20050096375
    Abstract: The present invention relates to a series of substituted bicyclic[3.1.0]amines of the Formula I: wherein A, B, D, Q, V, W, X, Y, Z, R2, R3, R4, R5, R14, R15, R30. o, p, s,t and q are as defined in the specification, their pharmaceutically acceptable salts, pharmaceutical compositions thereof, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.
    Type: Application
    Filed: October 14, 2004
    Publication date: May 5, 2005
    Inventors: Stanton McHardy, John Lowe
  • Pyridylamino compounds and methods of use thereof
    Publication number: 20050080100
    Abstract: This invention relates to a series of pyridylamino compounds of the formula I wherein Z1, Z2, W, X, Y and R1 are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.
    Type: Application
    Filed: August 26, 2004
    Publication date: April 14, 2005
    Inventor: John Lowe
  • Second person review of email
    Publication number: 20050050145
    Abstract: An email review tool gives users a simple, quick, and safe method of initiating review of an email document. The email review tool may provide a window to a user which allows the user to select another person to review the email or skip the review process and send the email directly to the recipients. Transmission of the email is thus deferred until the email has been reviewed.
    Type: Application
    Filed: September 3, 2003
    Publication date: March 3, 2005
    Inventor: John Lowe
  • 2-amino-6(2,4,5-substitued-phenyl)-pyridines
    Publication number: 20050032847
    Abstract: The present invention relates to pharmaceutical compositions containing the compounds 6-[4-(N-methyl-3-azetidinoxy)-5-ethyl-2-methoxy-phenyl]-pyridin-2-ylamine, 6-[4-(N,N-dimethylaminomethyl)-5-ethyl-2-methoxy-phenyl]-pyridin-2-ylamine, 6-[4-(N-methylaminomethyl)-5-ethyl-2-methoxy-phenyl]-pyridin-2-ylamine and 6-[4-(3-azetidinoxy)-5-ethyl-2-methoxy-phenyl]-pyridin-2-ylamine, and the pharmaceutically acceptable salts thereof, and to the use of such compounds in the treatment and prevention of central nervous system and other disorders.
    Type: Application
    Filed: September 9, 2004
    Publication date: February 10, 2005
    Inventors: John Lowe, Robert Volkmann
  • Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams
    Publication number: 20040266781
    Abstract: The present invention relates to compounds of formula I 1
    Type: Application
    Filed: June 15, 2004
    Publication date: December 30, 2004
    Applicant: Pfizer Inc
    Inventors: John Lowe, Mark A. Sanner
  • Method for treating IgE-mediated disorders
    Publication number: 20040259077
    Abstract: The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.
    Type: Application
    Filed: March 2, 2004
    Publication date: December 23, 2004
    Applicant: Genentech, Inc.
    Inventors: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
  • Novel tetrahydroquinolines
    Publication number: 20040254193
    Abstract: The present invention relates to compounds of formula I 1
    Type: Application
    Filed: May 24, 2004
    Publication date: December 16, 2004
    Applicant: Pfizer Inc
    Inventor: John Lowe
  • 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
    Patent number: 6803470
    Abstract: The present invention relates to the compounds 6-[4-(N-methyl-3-azetidinoxy)-5-ethyl-2-methoxy-phenyl]-pyridin-2-ylamine, 6-[4-(N,N-dimethylaminomethyl)-5-ethyl-2-methoxy-phenyl]-pyridin-2-ylamine, 6-[4-(N-methylaminomethyl)-5-ethyl-2-methoxy-phenyl]-pyridin-2-ylamine and 6-[4-(3-azetidinoxy)-5-ethyl-2-methoxy-phenyl]-pyridin-2-ylamine, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds and to the use of such compounds in the treatment and prevention of central nervous system and other disorders.
    Type: Grant
    Filed: October 8, 2002
    Date of Patent: October 12, 2004
    Assignee: Pfizer Inc
    Inventors: John A. Lowe, III, Robert A. Volkmann
  • Substituted aromatic ethers as inhibitors of glycine transport
    Patent number: 6784299
    Abstract: This invention relates to a series of substituted aromatic ethers of the formula I wherein ring A and X and Y are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: August 31, 2004
    Assignee: Pfizer Inc.
    Inventor: John A. Lowe, III
  • Anti-IgE antibodies
    Patent number: 6761889
    Abstract: The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-lgE and the target molecule is lgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.
    Type: Grant
    Filed: April 1, 2002
    Date of Patent: July 13, 2004
    Assignee: Genentech, Inc.
    Inventors: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
  • 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
    Publication number: 20040077853
    Abstract: The invention provides compounds of formula VI 1
    Type: Application
    Filed: February 18, 2003
    Publication date: April 22, 2004
    Applicant: Pfizer Inc.
    Inventors: John A. Lowe, Robert A. Volkmann
  • Therapeutic compositions comprising anti-IGE antibodies and immunosuppressive agent
    Patent number: 6723833
    Abstract: The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of substituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: April 20, 2004
    Assignee: Genentech, Inc.
    Inventors: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
  • Anti-IgE antibodies
    Patent number: 6682735
    Abstract: The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: January 27, 2004
    Assignee: Genentech, Inc.
    Inventors: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
  • Combination treatment for depression and anxiety
    Publication number: 20040006135
    Abstract: The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with an NK-3 antagonist agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and an NK-3 antagonist.
    Type: Application
    Filed: March 12, 2003
    Publication date: January 8, 2004
    Applicant: Pfizer Inc.
    Inventors: Susan B. Sobolov-Jaynes, John A. Lowe, Stafford McLean